C3 transferase gene therapy for continuous conditional RhoA inhibition

Area of Science:

• Neuroscience
• Molecular Biology
• Gene Therapy

Background:

• Axon regeneration in the adult mammalian central nervous system (CNS) is hindered by inhibitory molecules.
• RhoA, a Rho family GTPase, acts as a crucial intracellular mediator for these inhibitory signals.
• The bacterial enzyme C3-ADP ribosyltransferase (C3) inhibits RhoA, thereby promoting axon outgrowth.

Purpose of the Study:

• To develop an effective gene therapy strategy for delivering the C3 enzyme to neurons.
• To overcome the limitations of C3 protein delivery, such as poor cell permeability and short action duration.
• To investigate methods for controlled and enhanced C3 expression in neural cells for promoting CNS axon regeneration.

Main Methods:

• Development of viral vectors for introducing the C3 gene into neurons or neuronal progenitors.
• Implementation of cell-autonomous (endogenous) and cell-nonautonomous (secretable/permeable) delivery strategies.
• Utilizing a Tet-On system for doxycycline-inducible transcriptional control of C3 expression.
• Assessment of in vitro process outgrowth on inhibitory chondroitin sulfate proteoglycan substrates.

Main Results:

• Viral vectors successfully delivered the C3 gene to neurons and neuronal progenitors.
• Both cell-autonomous and cell-nonautonomous C3 delivery promoted in vitro axon outgrowth.
• The Tet-On system provided conditional control over C3 expression.
• The developed gene therapy approach demonstrated potential for overcoming C3 delivery challenges.

Conclusions:

• Gene therapy offers a promising strategy for delivering C3 to promote CNS axon regeneration.
• The developed viral vectors provide a controllable and effective means to enhance axonal regrowth.
• These tools hold significant potential for therapeutic applications in CNS injuries and neurodegenerative diseases.